The in vitro synergistic activities of moxalactam, cefoperazone, or cefotaxime in combination with amikacin or piperacillin were compared against aminoglycoside-susceptible and aminoglycoside-resistant isolates of Pseudomonas aeruginosa and Serratia marcescens by the checkerboard agar dilution method. All antimicrobial combinations demonstrated some synergy, and no antagonism was observed. Moxalactam plus amikacin and piperacillin plus amikacin were most frequently synergistic (two-thirds of the isolates inhibited synergistically by each combination), whereas combinations of moxalactam, cefotaxime, or cefoperazone with piperacillin were synergistic against only 18 to 25% of the isolates. Moxalactam plus amikacin was the combination most often synergistic for amikacinsusceptible P. aeruginosa, and piperacillin plus amikacin was the combination most frequently synergistic for amikacin-resistant P. aeruginosa and amikacinsusceptible S. marcescens. These results demonstrate frequent in vitro synergistic activity between the new beta-lactam agents and amikacin (especially moxalactam or piperacillin with amikacin), but comparative clinical trials are needed to establish the relative efficacy and toxicity of these combinations.
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Although well-controlled, definitive clinical studies are lacking, several animal and human studies suggest that Pseudomonas aeruginosa and Serratia marcescens infections may be favorably influenced by treatment with synergistic antimicrobial combinations consisting of an aminoglycoside plus carbenicillin or ticarcillin (1, 9, 16, 17, 22) . However, the usefulness of these specific combinations has been recently curtailed by the increasing resistance of P. aeruginosa and S. marcescens to carbenicillin and ticarcillin and even to some of the aminoglycosides (18, 20, 21) . Furthermore, a history of a severe allergic reaction to penicillin usually prohibits the use of carbenicillin or ticarcillin.
Moxalactam, cefoperazone, and cefotaxime are three new beta-lactam antimicrobial agents with remarkably wide spectra of in vitro antibacterial activity that include most P. aeruginosa and S. marcescens isolates as well as Escherichia coli, Klebsiella spp., Enterobacter spp., Proteus mirabilis, indole-positive Proteus spp., and Bacteroides fragilis (10) . These drugs also have inhbitory activity for many strains resistant to carbenicillin, ticarcillin, and the aminoglycosides (6, 11, 12 
MATERIALS AND METHODS
The organisms used in this study consisted of 50 strains of P. aeruginosa and 10 strains of S. marcescens. All were identified by standard criteria (3, (27) . The range of drug concentrations was the same for all drugs (0.06 to 512 pug/ml). An inoculum of 104 organisms diluted from broth cultures in the logarithmic phase of growth was delivered to the surface of antibiotic-containing agar, using the replicating device of Steers et al. (23) . Plates were inoculated within 4 h after being poured. The MIC of each antimicrobial agent either alone or in combination was the lowest concentration producing no visible growth. An antimicrobial combination was interpreted as synergistic if there was at least a fourfold decrease in the MIC of each antimicrobial agent (1, 9, 27) .
For selected antimicrobial combinations showing synergistic inhibitory activity, testing for possible synergistic bactericidal activity was carried out by the broth dilution method, using Mueller-Hinton broth and an inoculum of 5 x i0W organisms (26) . The antimicrobial agents were tested alone or in combination at concentrations ranging from 0.06 to 512 jg/ ml. The minimum bactericidal concentration was defined as the lowest concentration from which five or fewer colonies were subcultured on blood agar after incubation for 18 h at 370C.
RESULTS
The comparative synergistic activities of the beta-lactam antimicrobial agents and amikacin against P. aeruginosa and S. marcescens are summarized in Table 1 . Synergism was demonstrated with most of the combinations tested but occurred most often when a beta-lactam agent was combined with amikacin. The combinations of moxalactam plus amikacin and piperacillin plus amikacin were the most frequent synergistic combinations, and each combination had synergistic inhibitory activity against two-thirds of the isolates tested. In contrast, the antimicrobial combinations of moxalactam, cefotaxime, or cefoperazone with piperacillin were synergistic against 18 to 25% of the isolates tested. Moxalactam plus amikacin was the combination most often synergistic for amikacin-susceptible P. aeruginosa strains (79% inhibited synergistically by moxalactam plus amikacin), whereas piperacillin plus amikacin was the combination most frequently synergistic for amikacin-resistant P. aeruginosa isolates (88% inhibited synergistically by piperacillin plus amikacin). Piperacillin plus amikacin was also the only combination with synergistic activity against all 10 strains of amikacin-susceptible S. marcescens. No antagonism was observed with any of the antimicrobial combinations. Tables 2, 3 , and 4 summariz the MICs of each antimicrobial agent alone and in combination. For amikacin-susceptible P. aeruginosa (Table 2) , piperacillin and cefoperazone each had the greatest in vitro inhibitory activity among the beta-lactam agents alone (90% of the isolates inhibited by 16 ltg of either piperacillin or cefoperazone per ml), and piperacillin plus amikacin, cefoperazone plus amikacin, and moxalactam plus amikacin were the three antimicrobial combinations with the greatest in vitro activity on a weight basis. For amikacin-resistant P. aeruginosa (Table 3) , piperacillin and cefoperazone were also the most active beta-lactam agents alone (90% of the isolates inhibited by 8 ,ug of either piperacillin or cefoperazone per ml), whereas piperacillin plus amikacin was the most active antimicrobial combination on a weight basis. Finally, against the amikacin-susceptible S. marcescens (Table 4) , cefotaxime and moxalactam were the most active beta-lactam agents alone (90% of the strains inhibited by 2 ,ug of cefotaxime and 4 ,ug of moxalactam per ml), and cefotaxime plus amikacin and moxalactam plus amikacin were the most active antimicrobial combinations.
Eight isolates (three amikacin-susceptible P. aeruginosa, three amikacin-resistant P. aeruginosa, and two amikacin-susceptible S. marcescens) that were inhibited synergistically by both the moxalactam-amikacin and piperacillin-amikacin combinations were also tested for bactericidal synergy by these same combinations. Both the moxalactam-amikacin and piperacillinamikacin combinations had bactericidal synergy for six of these eight isolates, and the minimum bactericidal concentrations were within a onetube dilution of the MICs in each case. DISCUSSION The results of this study demonstrate that moxalactam, cefotaxime, or cefoperazone in combination with amikacin has significant in vitro synergistic antibacterial activity against many clinically significant P. aeruginosa and S. marcescens isolates, including organisms resistant to gentamicin and amikacin. Approximately synergism remains to be defined but is presumably related to enhancement of the penetration of amikacin into the bacterial cell by the betalactamn's inhibition of bacterial cell wall synthesis (8) .
Although the frequency of synergy with the beta-lactam-piperacillin combinations was not as great in this study as with the beta-lactamamikacin combinations, approximately 20 to 25% of the P. aeruginosa and S. marcescens isolates tested were still inhibited synergistically by moxalactam, cefotaxime, or cefoperazone plus piperacillin (Table 1) . Moreover, no antagonism was observed. Antagonism has been previously reported when certain penicillins and cephalosporins are combined (19) , and moxalactam combined with carbenicillin or ticarcillin has occasionally been antagonistic for P. aeruginosa organisms (29) . Thus, in addition to its greater activity on a weight basis than carbenicillin or ticarcillin against most gram-negative bacilli (28) bination of cephalothin plus an aminoglycoside has been previously reported to be significantly more nephrotoxic than either antimicrobial agent alone (25) . However, this concern over nephrotoxicity in certain patients might be avoided by taking advantage of the potential synergism between moxalactam, cefotaxime, or cefoperazone and piperacillin against certain strains of P. aeruginosa and S. marcescens.
